Blog Posts

DOSE OF REALITY: NEW STUDY DEBUNKS BIG PHARMA CLAIMS THAT HIGH PRESCRIPTION DRUG PRICES ARE TIED TO R&D INVESTMENTS

Sep 29, 2022

JAMA Network Open Paper Finds “No Relationship” Between Drug Company’s Read More

BIG PHARMA WATCH: BIOGEN TO PAY U.S. GOVERNMENT $900M FOR ANTI-COMPETITIVE KICKBACK SCHEME

Sep 27, 2022

Biogen Agrees to Settle Case Over Illegally Paying Doctors to Push Brand Name Read More

BIG PHARMA WATCH: CEO UNDERCUTS OWN INDUSTRY’S DOOM AND GLOOM RHETORIC ON RECENT DRUG PRICING SOLUTIONS

Sep 22, 2022

Novartis Exec Calls Policy to Keep Price Hikes Below Inflation Read More

DOSE OF REALITY: BIG PHARMA’S PRICING PRACTICES DRIVE CRISIS OF AFFORDABILITY FOR CANCER PATIENTS

Sep 20, 2022

Shining a Light on How Big Pharma is Rapidly Increasing Prices on Oncology Read More

BIG PHARMA WATCH: REPORT FINDS BIG PHARMA’S “PERVASIVE” PATENT ABUSE “THE ROOT OF THE DRUG PRICING CRISIS”

Sep 15, 2022

I-MAK Analysis Finds Anti-Competitive Practices That Extend Exclusivity Will Read More

BIG PHARMA WATCH: STUDY FINDS BIG PHARMA PROFITS THROUGH ANTI-COMPETITIVE KICKBACK SCHEMES CLOAKED AS CHARITY

Sep 9, 2022

Researchers Say Brand Name Drug Companies’ So-Called Patient Assistance Read More

SECOND OPINION: AVIK ROY DEBUNKS BIG PHARMA’S INNOVATION RHETORIC

Sep 1, 2022

FREOPP President Explains Pharmaceutical Industry Arguments Are “Factually Read More

BIG PHARMA WATCH: DRUG COMPANIES ON PACE FOR RECORD 2022 LAUNCH PRICES

Aug 16, 2022

Analysis Finds Brand Name Manufacturers Bringing New Drugs to Market with Read More

BIG PHARMA EARNINGS WATCH: ABBVIE, ASTRAZENECA, AMGEN

Aug 5, 2022

Big Pharma Drugmakers Top Wall Street Estimates After Hiking Drug Prices Read More

SECOND OPINION: PHRMA’S LAST-DITCH ATTEMPT TO DERAIL SOLUTIONS TO LOWER DRUG PRICES REHASHES DEBUNKED ARGUMENTS

Aug 5, 2022

Pharmaceutical Industry Attempts to Intimidate Lawmakers and Keep Prices High Read More

BIG PHARMA EARNINGS WATCH: PFIZER, MERCK, BRISTOL MYERS SQUIBB, GLAXOSMITHKLINE AND SANOFI

Jul 29, 2022

Big Pharma Giants All Top Analysts’ Expectations as Pharmaceutical Industry Read More